Home / Pharmaceutical / India Pharmaceutical Market: A Comprehensive Industry Analysis Q3 2013

India Pharmaceutical Market: A Comprehensive Industry Analysis Q3 2013

Published: Nov 2013 | No Of Pages: 161 | Published By: Kelly Scientific Publications

Product Synopsis

 
“Pharmaceutical Market: India, A Competitive Industry Analysis Q3 2013” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.  
 
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. This report describes the current therapeutics that are propelling the biopharmaceutical market in India and the main players in the industry. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. 
 
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets and is supported by over 330 exhibits. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
Current developments relating to patent expirations, government funding, and regulations are discussed.  The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed. 
The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in India. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. 
 
In summary, the Indian biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment. 
 
The main objectives of this report are:
 
  • To comprehensively summarize current developments in the Indian biopharmaceutical industry.
  • To identify emerging trends in key markets and sub-markets such as biogenerics, cardiology, oncology therapeutics, diabetic care, vaccines and anti-infective agents.
  • To comprehensive review and analyse financial and product details of key players in the industry
  • To present market figures of the current Indian biopharmaceutical market value and give forecast projections and growth rates
  • To identify key drivers and restraints of the Indian biopharmaceutical market
  • To report and analyse market opportunities and challenges
  • To identify funding and government sponsorship issues
 
The reader of this report will gain:
 
  • An in-depth understanding of the Indian biopharmaceutical market and it’s environment
  • Current market facts, figures and product lines of key players in the industry
  • An insight into how generic therapeutics will propagate the Indian biopharmaceutical market
  • Knowledge of how the Indian biopharma market will integrate into the global healthcare market 
  • Information on key government policies 
  • Data on levels of private and publically funded biopharma studies in India
  • Strategies on how to adapt and restructure current business models to this industry
 
This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. The following companies were chosen for analysis as they have specific advantages that we believe will drive the pharmaceutical industry in India. 
 
  • Aurobindo Pharma
  • Bharat Serums and Vaccines Ltd
  • Biocon Biopharmaceuticals
  • Cipla
  • Divis Laboratories
  • Dr Reddy’s Laboratories
  • Lupin
  • Mankind Pharma
  • Panacea Biotech
  • Piramal Group
  • Ranbaxy Laboratories
  • Reliance Life Sciences
  • Serum Institute of India
  • Sun Pharmaceuticals
  • Zydus Cadila
1.0 Summary 10
1.1 Objectives of Report 10
1.2 Scope of Study 11
1.3 Data Sources and Methodology 11
1.4 Key Findings and Observations 11
1.5 Executive Summary 12
 
2.0 Epidemiology and Disease Overview 16
2.1 Cardiovascular Disease 20
2.2 Infectious Disease 22
2.3 Respiratory Infections 22
2.4 Tuberculosis 24
2.5 HIV  29
2.6 Hepatitis  30
2.7 Typhoid Fever 31
2.8 Dengue Fever 31
2.9 Diabetes  31
2.10 Cancer  33
2.11 Chronic Respiratory Disease- Asthma and COPD  37
 
3.0 Twelfth Five Year Plan – A Boost for Scientific Research and Development   39
 
4.0 Economic and Business Environment 41
4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics  41
4.2 Gross Domestic Product of India, Historic and Projection Analysis    43
4.3 Global and India Economic Outlook 2010-2013  44
4.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe)   46
 
5.0 Indian Pharmaceutical Industry 49
5.1 Overview 49
5.2 Formulations Market 50
5.3 Active Pharmaceutical Ingredient Market 51
5.4 Biosimilar Market 52
5.5 Contract Research and Manufacturing Service (CRAMS) 52
5.6 Indian Pharmaceutical Industry Market 54
5.7 Evaluation of Market Share by Therapeutic Area  57
5.8 Key Players 58
 
6.0 Indian Pharmaceutical Company Profiles and Financial Data 60
6.1 Aurobindo Pharma 60
6.2 Bharat Serums and Vaccines Ltd 67
6.3 Biocon Biopharmaceuticals 69
6.4 Cipla  78
6.5 Divis Laboratories 82
6.6 Dr Reddy’s Laboratories 84
6.7 Lupin  89
6.8 Mankind Pharma 100
6.9 Panacea Biotech 106
6.10 Piramal Group 114
6.11 Ranbaxy Laboratories 120
6.12 Reliance Life Sciences 126
6.13 Serum Institute of India 129
6.14 Sun Pharmaceuticals 132
6.15 Zydus Cadila 136
 
7.0 SWOT Analysis of Indian Pharmaceutical Market  143
7.1 Growth Factors 143
7.2 Strengths of Indian Pharmaceutical Industry 144
7.3 Main Weaknesses 144
7.4 Significant Opportunities within the Indian Pharmaceutical Industry    145
7.5 Threats and Considerations 146
 
8.0 Company Directory and Key People 148
8.1 Aurobindo Pharma 148
8.2 Bharat Serums and Vaccines Ltd 149
8.3 Biocon Biopharmaceuticals 150
8.4 Cipla  152
8.5 Divis laboratories 152
8.6 Dr Reddy’s Laboratories 154
8.7 Lupin  156
8.8 Panacea Biotech 157
8.9 Reliance Life Sciences 159
 
9.0 Appendix 160
9.1  Comprehensive List of Pharmaceutical Company’s in India 160
Exhibit 2.1: Key Statistics: India 16
Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 – 2011 16
Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030 18
Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India   18
Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030 19
Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World 1970-2030 19
Exhibit 2.7: Cardiovascular Mortality by Indian State  20
Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India   21
Exhibit 2.9: Distribution of Cause of Death in Children under Five, India 22
Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia  23
Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children  23
Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present  24
Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates 2011  25
Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse and HIV Co-infection 25
Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases 2011  26
Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011 27
Exhibit 2.17: Countries That Had Notified of at Least One XDR-TB Case by end of 2011   27
Exhibit 2.18: TB Vaccine Development Pipeline 2012 28
Exhibit 2.19: HIV Prevalence in India 2004-2009  29
Exhibit 2.20:  Routes of HIV Transmission in India 2011 29
Exhibit 2.21: Global Hepatitis E Virus Endemicity  30
Exhibit 2.22: Prevalence of Diabetes by Indian Region 32
Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes, 2011  32
Exhibit 2.24:  Incidence and Mortality Rates for Top Sixteen Cancers in India – Both Sexes  33
Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female 34
Exhibit 2.26:  Incidence and Mortality Rates for Top Sixteen Cancers in India -  Men   34
Exhibit 2.27:  Incidence and Mortality Rates for Top Sixteen Cancers in India – Women   35
Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes  36
Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes  36
Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer’s in India 36
Exhibit 2.30: Mortality Rate Attributable to Chronic Obstructive Pulmonary Disease Globally  37
Exhibit 3.1: India’s Twelve Year Plan – Key Points in Relation to Science Research and Development 40
Exhibit 3.2: Budget for Specific Scientific Departments under India’s Twelfth Five Year Plan  40
Exhibit 4.1: World Trade Organisation Basic Indicators on India  41
Exhibit 4.2: World Trade Organisation Trade Policy of India 42
Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India 42
Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India   43
Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India 43
Exhibit 4.6: India GDP Figures 2011-2018   43
Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010 44
Exhibit 4.8: Global, Emerging Market and Developing Countries Economic Growth Change 2010-2013 44
Exhibit 4.9: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010- 2013  44
Exhibit 4.10: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013  44
Exhibit 4.11: Global, Emerging Market and Developing Countries and China Economic Growth Change 2010-2013  45
Exhibit 4.12: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013  46
Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013  46
Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017   47
Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013  47
Exhibit 4.16: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017  48
Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013  48
Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013  48
Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017  49
Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry  49
Exhibit 5.2: Indian Pharmaceutical Industry IPM and Exports 2003-2015 50
Exhibit 5.3: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015 50
Exhibit 5.4: Indian Pharmaceutical Industry Formulation Exports 2003-2015 51
Exhibit 5.5: Indian Pharmaceutical Industry Domestic Formulations 2003-2015 51
Exhibit 5.6: Geographic Distribution of India’s Active Pharmaceutical Ingredient Exports, 2012  52
Exhibit 5.7: Current Trends of the Global Biosimilar Market 52
Exhibit 5.8: Main Therapeutic Areas of the Future Biosimilar Market  53
Exhibit 5.9: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry  53
Exhibit 5.10: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry  54
Exhibit 5.11: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015  54
Exhibit 5.12: Leading Players of the Indian Pharmaceutical Market  54
Exhibit 5.13: India - Significant Economic Indicators   55
Exhibit 5.14: Positive Factors Influencing the Indian Pharmaceutical Market 55
Exhibit 5.15: Quantitative Market Share of Acute and Chronic Therapy in India, 2012   56
Exhibit 5.16: Multinational Company Penetration into Indian Pharmaceutical Market 2011  56
Exhibit 5.17: Key Factors Influencing Leading Player Position in India Pharma Market   57
Exhibit 5.18: Indian Pharmaceutical Market Share (%) by Therapeutic Area 57
Exhibit 5.19: Top Five Fastest Growing Indian Pharma Market Segments, 2012 57
Exhibit 5.20: Top Five Emerging Opportunities within the Indian Pharmaceutical Market   57
Exhibit 5.21: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue  58
Exhibit 5.22: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market  58
Exhibit 5.23: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012  59
Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest 60
Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation  60
Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations  60
Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest 61
Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio 61
Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio 61
Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio 62
Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio 62
Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio 62
Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio 62
Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio  62
Exhibit 6.12: Aurobindo Pharma Alzheimer’s Product Portfolio  62
Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio 62
Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio  63
Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio  63
Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio 63
Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio  63
Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio  64
Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio 64
Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio 65
Exhibit 6.21: Aurobindo Pharma Consolidated Revenue 2009-2012  65
Exhibit 6.22: Aurobindo Pharma Subsidiary Companies 66
Exhibit 6.23: Aurobindo Pharma Long Term Growth Strategies  67
Exhibit 6.24: Bharat Serums and Vaccines Significant Milestones  68
Exhibit 6.25: Bharat Serums and Vaccines Range of Products 68
Exhibit 6.26: Bharat Serums and Vaccines Plasma Serum Product Portfolio 68
Exhibit 6.27: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio   68
Exhibit 6.28: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio   68
Exhibit 6.29: Bharat Serums and Vaccines Cardiovascular Product Portfolio 69
Exhibit 6.30: Bharat Serums and Vaccines Anti-microbial Product Portfolio 69
Exhibit 6.31: Bharat Serums and Vaccines Anti-fungal Product Portfolio 69
Exhibit 6.32: Bharat Serums and Vaccines Anaesthesia Product Portfolio 69
Exhibit 6.33: Bharat Serums and Vaccines Hormone Product Portfolio  69
Exhibit 6.34: Biocon Biopharmaceuticals Business Outline 70
Exhibit 6.35: Biocon Biopharmaceuticals Five Key Business Areas  70
Exhibit 6.36: Biocon Biopharmaceuticals Subsidiary Companies  70
Exhibit 6.37: Biocon Biopharmaceuticals Important Milestones  71
Exhibit 6.38: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas  72
Exhibit 6.39: Biocon Biopharmaceuticals Active Biological Product Areas 72
Exhibit 6.40: Biocon Biopharmaceuticals Diabetes Branded Formulations 73
Exhibit 6.41: Biocon Biopharmaceuticals Oncology Branded Therapeutics 73
Exhibit 6.42: Biocon Biopharmaceuticals Nephrology Branded Therapeutics 73
Exhibit 6.43: Biocon Biopharmaceuticals Cardiology Branded Therapeutics 74
Exhibit 6.44: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics   74
Exhibit 6.45: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics 74
Exhibit 6.46: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics 75
Exhibit 6.47: Biocon Biopharmaceuticals – Syngene Service Platform  76
Exhibit 6.48: Biocon Biopharmaceuticals – Clinigene Service Platform  76
Exhibit 6.49: Biocon Biopharmaceuticals Revenue 2008-2012 77
Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2012 77
Exhibit 6.51: Biocon Biopharmaceuticals Profits from Operations 2008-2012 77
Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2012 78
Exhibit 6.53: Cipla Important Milestones   78
Exhibit 6.54: Cipla Main Therapeutics Areas of Interest 79
Exhibit 6.55: Cipla Export Market Share FY2011-2012 79
Exhibit 6.56: Cipla Sales and Other Income Exhibits 2003-2012  80
Exhibit 6.57: Cipla Profit after Tax Exhibits 2003-2012 80
Exhibit 6.58: Cipla Significant Product Launches During FY 2011-2012 81
Exhibit 6.59: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches During FY 2011-2012  81
Exhibit 6.60: Divis Laboratories Important Milestones 82
Exhibit 6.61: Divis Laboratories Product Category Portfolio 82
Exhibit 6.62: Divis Laboratories Product List  83
Exhibit 6.63: Divis Laboratories Income From Operations 2006-2012  84
Exhibit 6.64: Divis Laboratories Future Pipeline Portfolio 84
Exhibit 6.65: Dr Reddy’s Therapeutic Areas of Interest 85
Exhibit 6.66: Dr Reddy’s Laboratories – Important Milestones 85
Exhibit 6.67: Dr Reddy’s Labs Top Active Pharmaceutical Ingredients  86
Exhibit 6.68: Dr Reddy’s Labs Top Brands in India  86
Exhibit 6.69: Dr Reddy’s Laboratories Annual Revenue Exhibits 2003-2012 87
Exhibit 6.70: Dr Reddy’s Laboratories Historical Revenue Exhibits 2003-2012 (Global)   87
Exhibit 6.71: Dr Reddy’s Laboratories Geographical Revenue Percentage 2012 87
Exhibit 6.72: Dr Reddy’s Key Brand Revenue in Russia 2011-2012  88
Exhibit 6.73: Dr Reddy’s Key Brand Revenue in India 2011-2012  88
Exhibit 6.74: Dr Reddy’s Therapeutic Agents and Classes undergoing Clinical Trials   89
Exhibit 6.75: Lupin Significant Milestones   89
Exhibit 6.76: Lupin Ltd Formulations Product Portfolio 90
Exhibit 6.77: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio 92
Exhibit 6.78: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution  93
Exhibit 6.79: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012  93
Exhibit 6.80: Lupin Ltd  Formulation and Active Pharmaceutical Ingredient Revenue Contribution 2012 94
Exhibit 6.81: Lupin Ltd Geographic Breakdown of Revenue 2012  94
Exhibit 6.82: Lupin Ltd Net Global Sales 2008-2012  94
Exhibit 6.83a: Lupin Ltd Profit Before Tax 2008-2012 95
Exhibit 6.83b: Lupin Ltd Formulation Sales 2006-2012 Indian Market  95
Exhibit 6.84: Lupin Ltd Top Product Brands in the Indian Market and Ranking 96
Exhibit 6.85: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth 96
Exhibit 6.86: Lupin Pharma Key Products and Rank in the Indian Market 96
Exhibit 6.87: Lupin Respira Key Products and Rank in the Indian Market 96
Exhibit 6.88: Lupin Endeavour Key Products and Rank in the Indian Market 97
Exhibit 6.89: Lupin Maxter Key Products and Rank in the Indian Market 97
Exhibit 6.90: Lupin Pinnacle CVS Key Products and Rank in the Indian Market 97
Exhibit 6.90: Lupin Diabetes Care Key Products and Rank in the Indian Market 97
Exhibit 6.91: Lupin Mindvision Key Products and Rank in the Indian Market 97
Exhibit 6.92: Lupin Ikonic Key Products and Rank in the Indian Market 97
Exhibit 6.93: Lupin Pharmaceuticals Formulation Sales US Market 2007-2012 98
Exhibit 6.94: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market 98
Exhibit 6.95: Lupin Ltd Percentage Market Share within US Generics Market 99
Exhibit 6.96: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2012   99
Exhibit 6.97: Lupin Ltd Division of Sales by Therapeutic Area 100
Exhibit 6.98: Lupin Ltd Advanced Drug Delivery System Platform Portfolio 100
Exhibit 6.99: Lupin Ltd Research and Development Areas of Expertise  100
Exhibit 6.100: Mankind Pharma Company Divisions  101
Exhibit 6.101: Mankind Pharma Key Milestones  101
Exhibit 6.102: Mankind Pharma Therapeutic Areas of Interest 102
Exhibit 6.103: Mankind Pharma Prescription Product Areas 102
Exhibit 6.104: Mankind Pharma Top Ten Brands  102
Exhibit 6.105: Mankind Pharma Diabetic Product Brands 102
Exhibit 6.106: Mankind Pharma Hyperthyroidism Product Brands  103
Exhibit 6.107: Mankind Pharma Cough  Product Brands 103
Exhibit 6.108: Mankind Pharma Malaria Product Brands 103
Exhibit 6.109: Mankind Pharma Migraine Product Brands 103
Exhibit 6.110: Mankind Pharma Anti-viral Product Brands 103
Exhibit 6.111: Mankind Pharma Steroid Product Brands 103
Exhibit 6.112: Mankind Pharma Dermatology Product Brands 104
Exhibit 6.113: Mankind Pharma Ophthalmology Product Brands  104
Exhibit 6.114: Mankind Pharma Gynaecology Product Brands 104
Exhibit 6.115: Mankind Pharma Antibiotic Product Brands 105
Exhibit 6.116: Mankind Pharma Asthmatic Product Brands 105
Exhibit 6.117: Panacea Biotech Strategic Business Unit Structure  107
Exhibit 6.118: Panacea Biotech Therapeutic Areas of Interest 107
Exhibit 6.119: Panacea Biotech Leading Brands in India 107
Exhibit 6.120: Panacea Biotech Pain Management Therapy Portfolio  108
Exhibit 6.121: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycemic Product Range 108
Exhibit 6.122: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range 108
Exhibit 6.123: Panacea Biotech Vaccine Portfolio  109
Exhibit 6.124: Panacea Biotech Diabetes Management Portfolio  109
Exhibit 6.125: Panacea Biotech Anti-Osteoporotic Portfolio 109
Exhibit 6.126: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio   109
Exhibit 6.127: Panacea Biotech Renal Disease Management Portfolio  109
Exhibit 6.128: Panacea Biotech Gastro Intestinal Product Portfolio  110
Exhibit 6.129: Panacea Biotech Constipation Product Portfolio 110
Exhibit 6.130: Panacea Biotech Tuberculosis Product Portfolio 110
Exhibit 6.131: Panacea Biotech Cough/Cold Product Portfolio 110
Exhibit 6.132: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care 110
Exhibit 6.133: Panacea Biotech Brand Standing and Market Share (India) - Pain Management  110
Exhibit 6.134: Panacea Biotech Brand Standing and Market Share (India) – Tuberculosis Treatment 110
Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) – Gastrointestinal Treatment 111
Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) – Anti-Haemorrhoidal  111
Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) – Penicillins   111
Exhibit 6.138: Panacea Biotech Current Patents for Licencing 111
Exhibit 6.139: Panacea Biotech Net Turnover 2002-2012 113
Exhibit 6.140: Panacea Biotech Net Turnover 2002-2012 113
Exhibit 6.141: Panacea Biotech Geographic Distribution of Sales, 2010-2012 114
Exhibit 6.142: Panacea Biotech Geographic Distribution of Sales, 2010-2012 114
Exhibit 6.143: Key Milestones in Piramal Group History 115
Exhibit 6.144: Piramal Distribution of Sales (Percentage) 2012 117
Exhibit 6.145: Piramal Distribution of Pharma Solutions Domestic and International Sales 2012  117
Exhibit 6.146: Piramal Pharma Solutions Sales from Domestic and International Assets 2011-2012  117
Exhibit 6.147: Piramal Oncology Therapeutic Pipeline 119
Exhibit 6.148: Piramal Inflammation Therapeutic Pipeline 119
Exhibit 6.149: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline 119
Exhibit 6.150: Piramal Infectious Disease Therapeutic Pipeline  119
Exhibit 6.151: Ranbaxy Laboratories – Therapeutic Markets of Interest  120
Exhibit 6.152: Ranbaxy’s Oral Platform Technologies using a Novel Drug Delivery System  120
Exhibit 6.153: Ranbaxy Laboratories - Top Ten Therapeutics 120
Exhibit 6.154: Ranbaxy Key Merger and Acquisition Activity since 2006  121
Exhibit 6.155: List of Ranbaxy Subsidiary Companies 121
Exhibit 6.156: Ranbaxy – Future Therapeutic Areas  122
Exhibit 6.157: Ranbaxy Global Sales by Geographical Region 123
Exhibit 6.158: Ranbaxy Global Sale Figures by Geographical Region  123
Exhibit 6.159: Ranbaxy Geographical Market Share Percentage  123
Exhibit 6.160: Ranbaxy Developed and Emerging Market Share 124
Exhibit 6.161: Ranbaxy Sales Figures, USA and Canada 124
Exhibit 6.162: Ranbaxy Sales Figures, Europe  125
Exhibit 6.163: Ranbaxy Top Sellers in India   125
Exhibit 6.164: Ranbaxy Sales Figures, India   126
Exhibit 6.165: Ranbaxy Market Share of Top Therapeutics, India 126
Exhibit 6.166: Ranbaxy Launches by Geographical Region 126
Exhibit 6.167: Reliance Life Sciences Biopharmaceutical Product Areas 127
Exhibit 6.168: Reliance Life Sciences Pharmaceutical Product Areas  127
Exhibit 6.169: Reliance Life Sciences Clinical Research Services  128
Exhibit 6.170: Reliance Life Sciences Regenerative Medicine Product Areas 128
Exhibit 6.171: Reliance Life Sciences Molecular Medicine Product Areas 128
Exhibit 6.172: Reliance Life Science Plasma Protein Product Portfolio  128
Exhibit 6.173: Reliance Life Science Biosimilar Product Portfolio  128
Exhibit 6.174: Reliance Life Science Pharmaceutical Product Portfolio  128
Exhibit 6.175: Reliance Life Science Regenerative Medicine Product Portfolio 128
Exhibit 6.176: Reliance Life Science R&D Activities  129
Exhibit 6.177: Serum Institute of India Significant Milestones 130
Exhibit 6.178a: Serum Institute of India Manufactured Products  130
Exhibit 6.178b: Serum Institute of India Marketed Products 131
Exhibit 6.179: Serum Institute of India Exported Products 131
Exhibit 6.180: Serum Institute of India Product Pipeline 132
Exhibit 6.181: Sun Pharmaceuticals – Important Milestones 133
Exhibit 6.182: Sun Pharmaceuticals Revenue Stream 2011-2012 (percentage) 134
Exhibit 6.183: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions) 134
Exhibit 6.184: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012  135
Exhibit 6.185: Sun Pharmaceuticals Top Ten Branded Generics in India  135
Exhibit 6.186: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area   136
Exhibit 6.187: Zydus Research Centre Speciality Areas of Research  137
Exhibit 6.188: Zydus Cadila Vaccine R&D Areas of Research 137
Exhibit 6.189: Zydus Cadila Global ‘Beyond the Billion’ Business Development Strategy   138
Exhibit 6.190: Zydus Cadila Top Formulation Brands in the Indian Market 138
Exhibit 6.191: Zydus Cadila New Molecular Entities in Development Pipeline 139
Exhibit 6.192: Zydus Cadila Biosimilar Therapeutics in Development Pipeline 139
Exhibit 6.193: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2012 140
Exhibit 6.194: Zydus Cadila Gross Sales 2006-2012  141
Exhibit 6.195: Zydus Cadila List of Subsidiary Companies 141
Exhibit 6.196: Zydus Cadila Key Acquisitions 1995-2012 142
Exhibit 6.197: Zydus Cadila Research and Development Areas of Interest 142
Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market  143
Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020  143
Exhibit 7.3: Strengths of the Indian Pharmaceutical Market 144
Exhibit 7.4: Weaknesses of the Indian Pharmaceutical Market 144
Exhibit 7.5: Opportunities within the Indian Pharmaceutical Market  145
Exhibit 7.6: Threats to the Indian Pharmaceutical Market 147
Exhibit 8.1: Aurobindo Pharma Key Contact Details  148
Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel  148
Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details  149
Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors  149
Exhibit 8.5: Biocon Biopharmaceuticals Key Contact Details 150
Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors 151
Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team  151
Exhibit 8.8: Cipla Executive Directors   152
Exhibit 8.9: Cipla Non-Executive/Independent Directors 152
Exhibit 8.10: Cipla Corporate Contact Details  152
Exhibit 8.11: Divis Laboratories Key Contact Details  152
Exhibit 8.12: Divis Laboratories Key People   154
Exhibit 8.13: Dr Reddy’s Laboratories Contact Information 154
Exhibit 8.14: Dr Reddy’s Laboratories Key People  155
Exhibit 8.15: Dr Reddy’s Laboratories Board of Directors 155
Exhibit 8.16: Dr Reddy’s Audit Committee Members  156
Exhibit 8.17: Dr Reddy’s Nomination, Governance & Compensation Committee Members  156
Exhibit 8.18: Dr Reddy’s Risk Management Committee Members  156
Exhibit 8.19: Dr Reddy’s Science, Technology and Operations Committee Members   156
Exhibit 8.20: Dr Reddy’s Shareholders’ Grievance Committee Members 156
Exhibit 8.21: Dr Reddy’s Investment Committee Members 156
Exhibit 8.22: Dr Reddy’s Management Committee Members 156
Exhibit 8.23: Lupin Board of Directors   156
Exhibit 8.24: Lupin Key Management Players  157
Exhibit 8.25: Lupin Ltd General Contact Details  157
Exhibit 8.26: Panacea Biotech – Whole Time Directors 157
Exhibit 8.27: Panacea Biotech – Independent Directors 157
Exhibit 8.28: Panacea Biotech – Investor Contact Details 158
Exhibit 8.29: Panacea Biotech – General Contact Details 158
Exhibit 8.30: Reliance Life Sciences – General Contact Details  159
Exhibit 2.1: Key Statistics: India 16
Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 – 2011 16
Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030 18
Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India  18
Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030 19
Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World 1970-2030 19
Exhibit 2.7: Cardiovascular Mortality by Indian State 20
Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India  21
Exhibit 2.9: Distribution of Cause of Death in Children under Five, India 22
Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia 23
Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children 23
Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present 24
Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates 2011 25
Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse 
  and HIV Co-infection 25
Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases 2011 26
Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011 27
Exhibit 2.17: Countries That Had Notified of at Least One XDR-TB Case by end of 2011  27
Exhibit 2.18: TB Vaccine Development Pipeline 2012 28
Exhibit 2.19: HIV Prevalence in India 2004-2009 29
Exhibit 2.20: Routes of HIV Transmission in India 2011 29
Exhibit 2.21: Global Hepatitis E Virus Endemicity 30
Exhibit 2.22: Prevalence of Diabetes by Indian Region 32
Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes, 2011 32
Exhibit 2.24: Incidence and Mortality Rates for Top Sixteen Cancers in India – Both Sexes 33
Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female 34
Exhibit 2.26: Incidence and Mortality Rates for Top Sixteen Cancers in India - Men  34
Exhibit 2.27: Incidence and Mortality Rates for Top Sixteen Cancers in India – Women  35
Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes 36
Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes 36
Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer’s in India 36
Exhibit 2.30: Mortality Rate Attributable to Chronic Obstructive Pulmonary Disease Globally 37
Exhibit 3.1: India’s Twelve Year Plan – Key Points in Relation to Science Research and Development 40
Exhibit 3.2: Budget for Specific Scientific Departments under India’s Twelfth Five Year Plan 40
Exhibit 4.1: World Trade Organisation Basic Indicators on India 41
Exhibit 4.2: World Trade Organisation Trade Policy of India 42
Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India 42
Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India  43
Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India 43
Exhibit 4.6: India GDP Figures 2011-2018  43
Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010 44
Exhibit 4.8: Global, Emerging Market and Developing Countries Economic Growth Change 2010-2013 44
Exhibit 4.9: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010- 2013 44
Exhibit 4.10: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013 44
Exhibit 4.11: Global, Emerging Market and Developing Countries and China Economic Growth Change 2010-2013 45
Exhibit 4.12: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 46
Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013 46
Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017  47
Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013 47
Exhibit 4.16: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017 48
Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013 48
Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013 48
Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017 49
Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry 49
Exhibit 5.2: Indian Pharmaceutical Industry IPM and Exports 2003-2015 50
Exhibit 5.3: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015 50
Exhibit 5.4: Indian Pharmaceutical Industry Formulation Exports 2003-2015 51
Exhibit 5.5: Indian Pharmaceutical Industry Domestic Formulations 2003-2015 51
Exhibit 5.6: Geographic Distribution of India’s Active Pharmaceutical Ingredient Exports, 2012 52
Exhibit 5.7: Current Trends of the Global Biosimilar Market 52
Exhibit 5.8: Main Therapeutic Areas of the Future Biosimilar Market 53
Exhibit 5.9: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry 53
Exhibit 5.10: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry 54
Exhibit 5.11: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015 54
Exhibit 5.12: Leading Players of the Indian Pharmaceutical Market 54
Exhibit 5.13: India - Significant Economic Indicators  55
Exhibit 5.14: Positive Factors Influencing the Indian Pharmaceutical Market 55
Exhibit 5.15: Quantitative Market Share of Acute and Chronic Therapy in India, 2012  56
Exhibit 5.16: Multinational Company Penetration into Indian Pharmaceutical Market 2011 56
Exhibit 5.17: Key Factors Influencing Leading Player Position in India Pharma Market  57
Exhibit 5.18: Indian Pharmaceutical Market Share (%) by Therapeutic Area 57
Exhibit 5.19: Top Five Fastest Growing Indian Pharma Market Segments, 2012 57
Exhibit 5.20: Top Five Emerging Opportunities within the Indian Pharmaceutical Market  57
Exhibit 5.21: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue 58
Exhibit 5.22: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market 58
Exhibit 5.23: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012 59
Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest 60
Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation 60
Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations 60
Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest 61
Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio 61
Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio 61
Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio 62
Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio 62
Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio 62
Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio 62
Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio 62
Exhibit 6.12: Aurobindo Pharma Alzheimer’s Product Portfolio 62
Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio 62
Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio 63
Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio 63
Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio 63
Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio 63
Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio 64
Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio 64
Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio 65
Exhibit 6.21: Aurobindo Pharma Consolidated Revenue 2009-2012 65
Exhibit 6.22: Aurobindo Pharma Subsidiary Companies 66
Exhibit 6.23: Aurobindo Pharma Long Term Growth Strategies 67
Exhibit 6.24: Bharat Serums and Vaccines Significant Milestones 68
Exhibit 6.25: Bharat Serums and Vaccines Range of Products 68
Exhibit 6.26: Bharat Serums and Vaccines Plasma Serum Product Portfolio 68
Exhibit 6.27: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio  68
Exhibit 6.28: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio  68
Exhibit 6.29: Bharat Serums and Vaccines Cardiovascular Product Portfolio 69
Exhibit 6.30: Bharat Serums and Vaccines Anti-microbial Product Portfolio 69
Exhibit 6.31: Bharat Serums and Vaccines Anti-fungal Product Portfolio 69
Exhibit 6.32: Bharat Serums and Vaccines Anaesthesia Product Portfolio 69
Exhibit 6.33: Bharat Serums and Vaccines Hormone Product Portfolio 69
Exhibit 6.34: Biocon Biopharmaceuticals Business Outline 70
Exhibit 6.35: Biocon Biopharmaceuticals Five Key Business Areas 70
Exhibit 6.36: Biocon Biopharmaceuticals Subsidiary Companies 70
Exhibit 6.37: Biocon Biopharmaceuticals Important Milestones 71
Exhibit 6.38: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas 72
Exhibit 6.39: Biocon Biopharmaceuticals Active Biological Product Areas 72
Exhibit 6.40: Biocon Biopharmaceuticals Diabetes Branded Formulations 73
Exhibit 6.41: Biocon Biopharmaceuticals Oncology Branded Therapeutics 73
Exhibit 6.42: Biocon Biopharmaceuticals Nephrology Branded Therapeutics 73
Exhibit 6.43: Biocon Biopharmaceuticals Cardiology Branded Therapeutics 74
Exhibit 6.44: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics  74
Exhibit 6.45: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics 74
Exhibit 6.46: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics 75
Exhibit 6.47: Biocon Biopharmaceuticals – Syngene Service Platform 76
Exhibit 6.48: Biocon Biopharmaceuticals – Clinigene Service Platform 76
Exhibit 6.49: Biocon Biopharmaceuticals Revenue 2008-2012 77
Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2012 77
Exhibit 6.51: Biocon Biopharmaceuticals Profits from Operations 2008-2012 77
Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2012 78
Exhibit 6.53: Cipla Important Milestones  78
Exhibit 6.54: Cipla Main Therapeutics Areas of Interest 79
Exhibit 6.55: Cipla Export Market Share FY2011-2012 79
Exhibit 6.56: Cipla Sales and Other Income Exhibits 2003-2012 80
Exhibit 6.57: Cipla Profit after Tax Exhibits 2003-2012 80
Exhibit 6.58: Cipla Significant Product Launches During FY 2011-2012 81
Exhibit 6.59: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches During FY 2011-2012 81
Exhibit 6.60: Divis Laboratories Important Milestones 82
Exhibit 6.61: Divis Laboratories Product Category Portfolio 82
Exhibit 6.62: Divis Laboratories Product List 83
Exhibit 6.63: Divis Laboratories Income From Operations 2006-2012 84
Exhibit 6.64: Divis Laboratories Future Pipeline Portfolio 84
Exhibit 6.65: Dr Reddy’s Therapeutic Areas of Interest 85
Exhibit 6.66: Dr Reddy’s Laboratories – Important Milestones 85
Exhibit 6.67: Dr Reddy’s Labs Top Active Pharmaceutical Ingredients 86
Exhibit 6.68: Dr Reddy’s Labs Top Brands in India 86
Exhibit 6.69: Dr Reddy’s Laboratories Annual Revenue Exhibits 2003-2012 87
Exhibit 6.70: Dr Reddy’s Laboratories Historical Revenue Exhibits 2003-2012 (Global)  87
Exhibit 6.71: Dr Reddy’s Laboratories Geographical Revenue Percentage 2012 87
Exhibit 6.72: Dr Reddy’s Key Brand Revenue in Russia 2011-2012 88
Exhibit 6.73: Dr Reddy’s Key Brand Revenue in India 2011-2012 88
Exhibit 6.74: Dr Reddy’s Therapeutic Agents and Classes undergoing Clinical Trials  89
Exhibit 6.75: Lupin Significant Milestones  89
Exhibit 6.76: Lupin Ltd Formulations Product Portfolio 90
Exhibit 6.77: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio 92
Exhibit 6.78: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution 93
Exhibit 6.79: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012 93
Exhibit 6.80: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Revenue Contribution 2012 94
Exhibit 6.81: Lupin Ltd Geographic Breakdown of Revenue 2012 94
Exhibit 6.82: Lupin Ltd Net Global Sales 2008-2012 94
Exhibit 6.83a: Lupin Ltd Profit Before Tax 2008-2012 95
Exhibit 6.83b: Lupin Ltd Formulation Sales 2006-2012 Indian Market 95
Exhibit 6.84: Lupin Ltd Top Product Brands in the Indian Market and Ranking 96
Exhibit 6.85: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth 96
Exhibit 6.86: Lupin Pharma Key Products and Rank in the Indian Market 96
Exhibit 6.87: Lupin Respira Key Products and Rank in the Indian Market 96
Exhibit 6.88: Lupin Endeavour Key Products and Rank in the Indian Market 97
Exhibit 6.89: Lupin Maxter Key Products and Rank in the Indian Market 97
Exhibit 6.90: Lupin Pinnacle CVS Key Products and Rank in the Indian Market 97
Exhibit 6.90: Lupin Diabetes Care Key Products and Rank in the Indian Market 97
Exhibit 6.91: Lupin Mindvision Key Products and Rank in the Indian Market 97
Exhibit 6.92: Lupin Ikonic Key Products and Rank in the Indian Market 97
Exhibit 6.93: Lupin Pharmaceuticals Formulation Sales US Market 2007-2012 98
Exhibit 6.94: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market 98
Exhibit 6.95: Lupin Ltd Percentage Market Share within US Generics Market 99
Exhibit 6.96: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2012  99
Exhibit 6.97: Lupin Ltd Division of Sales by Therapeutic Area 100
Exhibit 6.98: Lupin Ltd Advanced Drug Delivery System Platform Portfolio 100
Exhibit 6.99: Lupin Ltd Research and Development Areas of Expertise 100
Exhibit 6.100: Mankind Pharma Company Divisions 101
Exhibit 6.101: Mankind Pharma Key Milestones 101
Exhibit 6.102: Mankind Pharma Therapeutic Areas of Interest 102
Exhibit 6.103: Mankind Pharma Prescription Product Areas 102
Exhibit 6.104: Mankind Pharma Top Ten Brands 102
Exhibit 6.105: Mankind Pharma Diabetic Product Brands 102
Exhibit 6.106: Mankind Pharma Hyperthyroidism Product Brands 103
Exhibit 6.107: Mankind Pharma Cough Product Brands 103
Exhibit 6.108: Mankind Pharma Malaria Product Brands 103
Exhibit 6.109: Mankind Pharma Migraine Product Brands 103
Exhibit 6.110: Mankind Pharma Anti-viral Product Brands 103
Exhibit 6.111: Mankind Pharma Steroid Product Brands 103
Exhibit 6.112: Mankind Pharma Dermatology Product Brands 104
Exhibit 6.113: Mankind Pharma Ophthalmology Product Brands 104
Exhibit 6.114: Mankind Pharma Gynaecology Product Brands 104
Exhibit 6.115: Mankind Pharma Antibiotic Product Brands 105
Exhibit 6.116: Mankind Pharma Asthmatic Product Brands 105
Exhibit 6.117: Panacea Biotech Strategic Business Unit Structure 107
Exhibit 6.118: Panacea Biotech Therapeutic Areas of Interest 107
Exhibit 6.119: Panacea Biotech Leading Brands in India 107
Exhibit 6.120: Panacea Biotech Pain Management Therapy Portfolio 108
Exhibit 6.121: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycemic Product Range 108
Exhibit 6.122: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range 108
Exhibit 6.123: Panacea Biotech Vaccine Portfolio 109
Exhibit 6.124: Panacea Biotech Diabetes Management Portfolio 109
Exhibit 6.125: Panacea Biotech Anti-Osteoporotic Portfolio 109
Exhibit 6.126: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio  109
Exhibit 6.127: Panacea Biotech Renal Disease Management Portfolio 109
Exhibit 6.128: Panacea Biotech Gastro Intestinal Product Portfolio 110
Exhibit 6.129: Panacea Biotech Constipation Product Portfolio 110
Exhibit 6.130: Panacea Biotech Tuberculosis Product Portfolio 110
Exhibit 6.131: Panacea Biotech Cough/Cold Product Portfolio 110
Exhibit 6.132: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care 110
Exhibit 6.133: Panacea Biotech Brand Standing and Market Share (India) - Pain Management 110
Exhibit 6.134: Panacea Biotech Brand Standing and Market Share (India) – Tuberculosis Treatment 110
Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) – Gastrointestinal Treatment 111
Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) – Anti-Haemorrhoidal 111
Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) – Penicillins  111
Exhibit 6.138: Panacea Biotech Current Patents for Licencing 111
Exhibit 6.139: Panacea Biotech Net Turnover 2002-2012 113
Exhibit 6.140: Panacea Biotech Net Turnover 2002-2012 113
Exhibit 6.141: Panacea Biotech Geographic Distribution of Sales, 2010-2012 114
Exhibit 6.142: Panacea Biotech Geographic Distribution of Sales, 2010-2012 114
Exhibit 6.143: Key Milestones in Piramal Group History 115
Exhibit 6.144: Piramal Distribution of Sales (Percentage) 2012 117
Exhibit 6.145: Piramal Distribution of Pharma Solutions Domestic and International Sales 2012 117
Exhibit 6.146: Piramal Pharma Solutions Sales from Domestic and International Assets 2011-2012 117
Exhibit 6.147: Piramal Oncology Therapeutic Pipeline 119
Exhibit 6.148: Piramal Inflammation Therapeutic Pipeline 119
Exhibit 6.149: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline 119
Exhibit 6.150: Piramal Infectious Disease Therapeutic Pipeline 119
Exhibit 6.151: Ranbaxy Laboratories – Therapeutic Markets of Interest 120
Exhibit 6.152: Ranbaxy’s Oral Platform Technologies using a Novel Drug Delivery System 120
Exhibit 6.153: Ranbaxy Laboratories - Top Ten Therapeutics 120
Exhibit 6.154: Ranbaxy Key Merger and Acquisition Activity since 2006 121
Exhibit 6.155: List of Ranbaxy Subsidiary Companies 121
Exhibit 6.156: Ranbaxy – Future Therapeutic Areas 122
Exhibit 6.157: Ranbaxy Global Sales by Geographical Region 123
Exhibit 6.158: Ranbaxy Global Sale Figures by Geographical Region 123
Exhibit 6.159: Ranbaxy Geographical Market Share Percentage 123
Exhibit 6.160: Ranbaxy Developed and Emerging Market Share 124
Exhibit 6.161: Ranbaxy Sales Figures, USA and Canada 124
Exhibit 6.162: Ranbaxy Sales Figures, Europe 125
Exhibit 6.163: Ranbaxy Top Sellers in India  125
Exhibit 6.164: Ranbaxy Sales Figures, India  126
Exhibit 6.165: Ranbaxy Market Share of Top Therapeutics, India 126
Exhibit 6.166: Ranbaxy Launches by Geographical Region 126
Exhibit 6.167: Reliance Life Sciences Biopharmaceutical Product Areas 127
Exhibit 6.168: Reliance Life Sciences Pharmaceutical Product Areas 127
Exhibit 6.169: Reliance Life Sciences Clinical Research Services 128
Exhibit 6.170: Reliance Life Sciences Regenerative Medicine Product Areas 128
Exhibit 6.171: Reliance Life Sciences Molecular Medicine Product Areas 128
Exhibit 6.172: Reliance Life Science Plasma Protein Product Portfolio 128
Exhibit 6.173: Reliance Life Science Biosimilar Product Portfolio 128
Exhibit 6.174: Reliance Life Science Pharmaceutical Product Portfolio 128
Exhibit 6.175: Reliance Life Science Regenerative Medicine Product Portfolio 128
Exhibit 6.176: Reliance Life Science R&D Activities 129
Exhibit 6.177: Serum Institute of India Significant Milestones 130
Exhibit 6.178a: Serum Institute of India Manufactured Products 130
Exhibit 6.178b: Serum Institute of India Marketed Products 131
Exhibit 6.179: Serum Institute of India Exported Products 131
Exhibit 6.180: Serum Institute of India Product Pipeline 132
Exhibit 6.181: Sun Pharmaceuticals – Important Milestones 133
Exhibit 6.182: Sun Pharmaceuticals Revenue Stream 2011-2012 (percentage) 134
Exhibit 6.183: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions) 134
Exhibit 6.184: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012 135
Exhibit 6.185: Sun Pharmaceuticals Top Ten Branded Generics in India 135
Exhibit 6.186: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area  136
Exhibit 6.187: Zydus Research Centre Speciality Areas of Research 137
Exhibit 6.188: Zydus Cadila Vaccine R&D Areas of Research 137
Exhibit 6.189: Zydus Cadila Global ‘Beyond the Billion’ Business Development Strategy  138
Exhibit 6.190: Zydus Cadila Top Formulation Brands in the Indian Market 138
Exhibit 6.191: Zydus Cadila New Molecular Entities in Development Pipeline 139
Exhibit 6.192: Zydus Cadila Biosimilar Therapeutics in Development Pipeline 139
Exhibit 6.193: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2012 140
Exhibit 6.194: Zydus Cadila Gross Sales 2006-2012 141
Exhibit 6.195: Zydus Cadila List of Subsidiary Companies 141
Exhibit 6.196: Zydus Cadila Key Acquisitions 1995-2012 142
Exhibit 6.197: Zydus Cadila Research and Development Areas of Interest 142
Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market 143
Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020 143
Exhibit 7.3: Strengths of the Indian Pharmaceutical Market 144
Exhibit 7.4: Weaknesses of the Indian Pharmaceutical Market 144
Exhibit 7.5: Opportunities within the Indian Pharmaceutical Market 145
Exhibit 7.6: Threats to the Indian Pharmaceutical Market 147
Exhibit 8.1: Aurobindo Pharma Key Contact Details 148
Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel 148
Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details 149
Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors 149
Exhibit 8.5: Biocon Biopharmaceuticals Key Contact Details 150
Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors 151
Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team 151
Exhibit 8.8: Cipla Executive Directors  152
Exhibit 8.9: Cipla Non-Executive/Independent Directors 152
Exhibit 8.10: Cipla Corporate Contact Details 152
Exhibit 8.11: Divis Laboratories Key Contact Details 152
Exhibit 8.12: Divis Laboratories Key People  154
Exhibit 8.13: Dr Reddy’s Laboratories Contact Information 154
Exhibit 8.14: Dr Reddy’s Laboratories Key People 155
Exhibit 8.15: Dr Reddy’s Laboratories Board of Directors 155
Exhibit 8.16: Dr Reddy’s Audit Committee Members 156
Exhibit 8.17: Dr Reddy’s Nomination, Governance & Compensation Committee Members 156
Exhibit 8.18: Dr Reddy’s Risk Management Committee Members 156
Exhibit 8.19: Dr Reddy’s Science, Technology and Operations Committee Members  156
Exhibit 8.20: Dr Reddy’s Shareholders’ Grievance Committee Members 156
Exhibit 8.21: Dr Reddy’s Investment Committee Members 156
Exhibit 8.22: Dr Reddy’s Management Committee Members 156
Exhibit 8.23: Lupin Board of Directors  156
Exhibit 8.24: Lupin Key Management Players 157
Exhibit 8.25: Lupin Ltd General Contact Details 157
Exhibit 8.26: Panacea Biotech – Whole Time Directors 157
Exhibit 8.27: Panacea Biotech – Independent Directors 157
Exhibit 8.28: Panacea Biotech – Investor Contact Details 158
Exhibit 8.29: Panacea Biotech – General Contact Details 158
Exhibit 8.30: Reliance Life Sciences – General Contact Details 159
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +